Mosquirix Vaccine –An Overview

Mosquirix Vaccine –An Overview

Author Name : Dr. Ajith J S, Vivek Gaikwad, Rahul Thorat, Tejas More

ABSTRACT

Malaria is a acute fever, serious and life threatening disease caused in humans by bite of female anopheles mosquito. plasmodium falciform, p. vivax p.ovule curtisi, p.ovule wallkeri, p.malarie and the extremely rare p.knowleri this are the 6 single-celled eukaryotic plasmodium parasite which cause malaria in humans. From them p. falsiform and p. vivax are the major cause of malaria, over the years malaria is the primary cause of child illness and deaths to overcome this epidemic WHO and R&D sector of majority of countries working on it, GSK with the partnership of PATH with the support of African research Centre developed a RTS,S vaccine after reviewing its safety and effectiveness European medicine agency (EMA) approved it in 2015. And later in October 2021 WHO approve the vaccine for broad use in children. It is the first license vaccine approved for use against any type of human parasitic disease. Mosquirix is a vaccine given to children aged 6 weeks to 17 months to help protect against malaria caused by the parasite p.falciparam. Mosquirix is given as a 0.5 ml injection in child at interval of 1 month and it is effective at reducing the number of children who have p.falciparum malaria. Mosquirix was also shown to induce antibodies against the hepatitis B virus at least as effectively as a currently authorized hepatitis B vaccine RTS,S/ Mosquirix vaccine has reached a significant milestone as the first vaccine against malaria but it has low efficacy ,now overcoming this issue and make it more effective against malaria is the new challenge for the researchers.